VERA Key Statistics, Chart & Performance
The current stock price of VERA is 50.64 USD. In the past month the price increased by 35.95%. In the past year, price increased by 17.17%.
VERA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About VERA
Company Profile
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 224 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
Company Info
VERA THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 1200
Brisbane California CALIFORNIA 14623 US
CEO: Marshall Fordyce
Employees: 224
Phone: 16507700077
VERA THERAPEUTICS INC / VERA FAQ
What does VERA THERAPEUTICS INC do?
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 224 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
Can you provide the latest stock price for VERA THERAPEUTICS INC?
The current stock price of VERA is 50.64 USD. The price decreased by -1.04% in the last trading session.
Does VERA THERAPEUTICS INC pay dividends?
VERA does not pay a dividend.
What is the ChartMill rating of VERA THERAPEUTICS INC stock?
VERA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for VERA stock?
20 analysts have analysed VERA and the average price target is 75.24 USD. This implies a price increase of 48.59% is expected in the next year compared to the current price of 50.64.
Would investing in VERA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VERA.
VERA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VERA. When comparing the yearly performance of all stocks, VERA is one of the better performing stocks in the market, outperforming 93.1% of all stocks.
VERA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERA. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability.
VERA Financial Highlights
Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -3.99. The EPS decreased by -51.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.68% | ||
| ROE | -63.16% | ||
| Debt/Equity | 0.19 |
VERA Forecast & Estimates
20 analysts have analysed VERA and the average price target is 75.24 USD. This implies a price increase of 48.59% is expected in the next year compared to the current price of 50.64.